Collegium Announces Appointment of Steven Passik, PhD, as Vice President, Scientific Affairs, Education and Policy
April 04 2017 - 8:24AM
Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced it has
appointed Steven Passik, PhD, as Vice President of Scientific
Affairs, Education and Policy, effective, April 3, 2017.
“We are excited to announce the addition of Steve to the
executive team. He will bring a wealth of additional experience in
the fields of pain and addiction management to the team at
Collegium. We are looking forward to his contributions toward our
vision of being a leader in pain management and
supporting responsible opioid prescribing,” said Mike
Heffernan, President and CEO of Collegium.
After a 25 year academic and clinical career at Memorial Sloan
Kettering Cancer Center, University of Kentucky and Vanderbilt
University, Dr. Passik spent the past 4 years in the toxicology and
most recently the pharmaceutical industry. His research has focused
on psychiatric aspects of cancer and non-cancer pain and symptom
management and the interface of pain management and addiction. He
has served as editor and reviewer for multiple journals in pain and
psycho-oncology. He has authored over 200 scholarly
publications.
About Collegium Pharmaceutical,
Inc.
Collegium is a specialty pharmaceutical company focused on
developing a portfolio of products that incorporate its proprietary
DETERx® technology platform for the treatment of chronic pain and
other diseases. The DETERx technology platform is designed to
provide extended-release delivery, unique abuse-deterrent
properties, and flexible dose administration options.
About Xtampza ER
Xtampza® ER is Collegium’s first product utilizing the DETERx
technology platform. Xtampza ER is an abuse-deterrent,
extended-release, oral formulation of oxycodone approved by the FDA
for the management of pain severe enough to require daily,
around-the-clock, long-term opioid treatment and for which
alternative treatment options are inadequate.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. We may, in some
cases, use terms such as "predicts," "believes," "potential,"
"proposed," "continue," "estimates," "anticipates," "expects,"
"plans," "intends," "may," "could," "might," "should" or other
words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. Such statements are
subject to numerous important factors, risks and uncertainties that
may cause actual events or results to differ materially from the
company's current expectations. Management's expectations and,
therefore, any forward-looking statements in this press release
could also be affected by risks and uncertainties relating to a
number of other factors, including the following: our ability to
obtain and maintain regulatory approval of our products and product
candidates, and any related restrictions, limitations, and/or
warnings in the label of an approved product; our plans to
commercialize our product candidates and grow sales of our
products; the size and growth potential of the markets for our
products and product candidates, and our ability to service those
markets; the success of competing products that are or become
available; our ability to obtain reimbursement and third-party
payor contracts for our products; the costs of commercialization
activities, including marketing, sales and distribution; our
ability to develop sales and marketing capabilities, whether alone
or with potential future collaborators; the rate and degree of
market acceptance of our products and product candidates; changing
market conditions for our products and product candidates; the
outcome of any patent infringement or other litigation that may be
brought against us, including litigation with Purdue Pharma, L.P.;
our ability to attract collaborators with development, regulatory
and commercialization expertise; the success, cost and timing of
our product development activities, studies and clinical trials;
our ability to obtain funding for our operations; regulatory
developments in the United States and foreign countries; our
expectations regarding our ability to obtain and adequately
maintain sufficient intellectual property protection for our
products and product candidates; our ability to operate our
business without infringing the intellectual property rights of
others; the performance of our third-party suppliers and
manufacturers; our ability to comply with stringent U.S. and
foreign government regulation in the manufacture of pharmaceutical
products, including U.S. Drug Enforcement Agency compliance; the
loss of key scientific or management personnel; our expectations
regarding the period during which we qualify as an emerging growth
company under the JOBS Act; and the accuracy of our estimates
regarding expenses, revenue, capital requirements and need for
additional financing. These and other risks are described
under the heading "Risk Factors" in our Annual Report on Form 10-K
for the year ended December 31, 2016, and those risks described
from time to time in other reports which we file with the SEC. Any
forward-looking statements that we make in this press release speak
only as of the date of this press release. We assume no obligation
to update our forward-looking statements whether as a result of new
information, future events or otherwise, after the date of this
press release.
Contact:
Alex Dasalla
adasalla@collegiumpharma.com
Collegium Pharmaceutical (NASDAQ:COLL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Collegium Pharmaceutical (NASDAQ:COLL)
Historical Stock Chart
From Apr 2023 to Apr 2024